Charles Cashion - Conatus Pharmaceuticals Insider

Conatus Pharmaceuticals Inc -- USA Stock  

USD 4.1  0.09  2.24%

CFO, Senior Vice President of Finance, Secretary

Mr. Charles J. Cashion is Chief Financial Officer, Senior Vice President of Finance, Secretary of Conatus Pharmaceuticals Inc., since July 2005. From 2001 to 2005, he was Chief Financial Officer at Idun. He has held several senior level management positions in both private and public healthcare companies with responsibilities for securing and executing various types of financings including initial public offerings, secondary offerings, corporate partnerships, and debt. He has also been involved with the strategic planning, acquisition and integration of several technology companies. He joined Idun Pharmaceuticals in 2001 as Executive Vice President, Chief Financial Officer and Secretary. Previously, he held the position of Senior Vice President and Chief Financial Officer of Quidel Corporationrationration, a publiclyheld medical diagnostics company. For the prior nine years, he was Senior Vice President, Finance, and Chief Financial Officer of The Immune Response Corporationrationration, a publiclyheld biopharmaceutical company. During the period from 1980 to 1989, he was Executive Vice President and Chief Financial Officer of Smith Laboratories, Inc., a publiclyheld pharmaceutical company and during 1987 through 1989 was also President and Chief Executive Officer of Sutter Corporationrationration, an orthopedic products subsidiary of Smith Laboratories. He also held positions at Baxter International, Inc. and Motorola, Inc. He serves on the boards of directors of NovaBay Pharmaceuticals, Inc., Ridge Diagnostics, Inc., La Jolla Institute for Allergy Immunology, and iDiverse, Inc
Age: 64  President Since 2005  MBA    
858-376-2600  http://www.conatuspharma.com
Cashion holds an M.B.A. and B.S. in Accounting from Northern Illinois University.

Management Efficiency

The company has return on total asset (ROA) of (23.97) % which means that it has lost $23.97 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (80.58) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 12.78 M in liabilities with Debt to Equity (D/E) ratio of 37.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Conatus Pharmaceuticals Inc has Current Ratio of 2.71 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Entity Summary

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Conatus Pharmaceuticals Inc (CNAT) is traded on NASDAQ General Markets in USA. It is located in CALIFORNIA, U.S.A and employs 25 people. Conatus Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Conatus Pharmaceuticals Inc to your portfolio

Top Management

Conatus Pharmaceuticals Leadership Team
Edward Smith, President, MBA
Michelle Vandertie, Executive
Dan Kisner, Director
James Scopa, Director
Steven Mento, CEO
Daniel Kisner, Director
Preston Klassen, Director
David Hale, Chairman
Harold Wart, Director, Ph.D
William LaRue, Director, MBA
Alfred Spada, Founder, Ph.D
Charles Cashion, President, MBA
Daniel Ripley, President, MBA
Keith Marshall, President, MBA
Louis Lacasse, Director, MBA
Shahzad Malik, Director
David Hagerty, President

Stock Performance

Conatus Pharmaceuticals Performance Indicators